Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.

Madoka Iwase Masashi AndoKenjiro AogiTomoyuki ArugaKenichiro InoueAkihiko ShimomuraEriko TokunagaNorikazu MasudaHideko YamauchiToshinari YamashitaHiroji Iwata

Published in: Breast cancer research and treatment (2020)

Addition of carboplatin to neoadjuvant chemotherapy significantly improved DFS and OS in patients with TNBC but not in those with hormone receptor-positive, HER2-negative breast cancer.

Keyphrases

neoadjuvant chemotherapy
locally advanced
phase ii study
lymph node
sentinel lymph node
rectal cancer
squamous cell carcinoma
radiation therapy
randomized controlled trial
phase iii
early stage
open label